Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 128 resultados

PhyloDRS: Phylogenomic-driven Drug Discovery from Rhodococcus and Saccharomonospora using 2D and 3D Cell Cultu... HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 The project titled, 'Phylogenomic-driven Drug Discovery from Rhodococcus and Saccharomonospora using 2D and 3D Cell Cultures' aims to explor...
2024-05-17 - 2026-07-31 | Financiado

InECFAb: Inhibitors of ECF transporters as novel antibacterial agents HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH tramitó un HORIZON EUROPE: ERC-2023-POC Antimicrobial resistance is a global health threat, urgently calling for the development of novel anti-infective strategies. We will adopt a...
2024-03-19 - 2025-09-30 | Financiado

CRISPR-SELECT: Harnessing a novel CRISPR nuclease for programmable counterselection in human cells HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH tramitó un HORIZON EUROPE: ERC-2023-POC CRISPR technologies have revolutionized genome editing in medicine, agriculture, biotechnology, and life-sciences research with their abilit...
2024-02-06 - 2025-09-30 | Financiado

KpIspE: Design and synthesis of novel inhibitors of the anti-infective target IspE HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Due to the current antimicrobial resistance crisis, addressing underexplored targets to afford anti-infective compounds with novel modes of...
2023-06-21 - 2025-08-31 | Financiado

AnLeadOp: Antibiotic Lead Optimization HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH tramitó un HORIZON EUROPE: ERC-2022-POC2 The bacterial sliding clamp (DnaN) is an innovative target for the development of novel antibiotics, which are urgently needed to overcome t...
2023-05-05 - 2024-11-30 | Financiado

SUNRISE: Strategies and Technologies for United and Resilient Critical Infrastructures and Vital Services in... HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH participó en un HORIZON EUROPE: HORIZON-CL3-2021-INFRA-01 The COVID-19 pandemic has highlighted the importance of the continuity of vital services, has shown the need to work together for the common...
2022-09-06 - 2025-09-30 | Financiado

TALENTS: Training AlliancE for Novel Microbiome-Modulating TherapieS HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 TALENTS aims to build up an international programme for interdisciplinary and transsectorial training of 15 doctoral candidates (DCs) as nee...
2022-09-02 - 2027-12-31 | Financiado

BCOMING: Biodiversity Conservation to Mitigate the risks of emerging infectious diseases HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH participó en un HORIZON EUROPE: HORIZON-CL6-2021-BIODIV-01 Biodiversity loss in hotspots of biodiversity is, among other socio-ecological factors, key to understand, prevent and react to future pande...
2022-06-08 - 2026-07-31 | Financiado

D-SOLVE: Understanding the individual host response against Hepatitis D Virus to develop a personalized appro... HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 Hepatitis D is by far the most severe form of chronic viral hepatitis frequently leading to liver failure, hepatocellular carcinoma and deat...
2022-05-25 - 2026-09-30 | Financiado

GUT-CHECK: Deciphering commensal-host-pathogen metabolic interactions to combat intestinal infections HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH participó en un HORIZON EUROPE: ERC-2021-STG Our intestinal tract offers an attractive environment for bacteria. The beneficial bacteria of our microbiota feast on undigested foods and...
2022-05-02 - 2027-08-31 | Financiado

ISIDORe: Integrated Services for Infectious Disease Outbreak Research HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH participó en un HORIZON EUROPE: HORIZON-INFRA-2021-EMERGENCY-02 The ISIDORe consortium, made of the capacities of European ESFRI infrastructures and coordinated networks, proposes to assemble the largest...
2022-02-09 - 2025-07-31 | Financiado

Inno4Vac: Innovations to accelerate vaccine development and manufacture HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Inno4Vac proposes an ambitious programme that will harness the latest advances in immunology, disease modelling, and modelling for tackling...
2021-07-19 - 2027-02-28 | Financiado

MONAGEL: anti pseudoMOnas aeruginosa biofilm NAno in hydroGEL HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH tramitó un H2020: H2020-MSCA-IF-2020 Pseudomonas aeruginosa (PA) is ubiquitous gram-negative bacteria. PA is a serious threat and is considered as a critical priority for treatm...
2021-07-18 - 2023-12-31 | Financiado

ModVaccine: Cross omics integration to identify modulators for improving vaccine efficacy HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH tramitó un H2020: ERC-2020-STG Influenza is a significant public health threat and vaccines are crucial for preventing infections at population-level. The efficacy of vacc...
2020-12-14 - 2025-12-31 | Financiado

HZI